Morales-Soriano, RafaelCuadrado Garcia, AngelNoguera Aguilar, Jose FranciscoDolz Abadia, CarlosVilella, AngelsRiera-Oliver, JoanGonzalez de Cabo, M.Arrivi, AntonioFalcó, EstherGarcia-Bonafe, M. MagdalenaCompany Campins, Maria MargaritaVicens, J. C.Socias Mir, Antonia2021-08-252021-08-252011-01Morales R., Cuadrado A., Noguera J. F., Dolz C., Vilella A., Riera J., et al. Multidisciplinary approach and multimodal therapy in resected pancreatic cancer. Observational study. Rev Esp Enferm Dig. 2011 Jan;103(1):5-12.1130-0108https://hdl.handle.net/20.500.13003/16726Objective: analysis and evaluation of a multidisciplinary approach, postoperative results and survival of a group of patients with resected pancreatic cancer after a multimodal therapy. Design: descriptive, prospective and observational study. Patients: between January 2004 and December 2004, 124 patients with pancreatic cancer were evaluated. In 30 patients pancreatic resection was performed, and they are the object of this study. Results of preoperative evaluation, postoperative morbidity and mortality, and long term survival were studied. Results: diagnostic evaluation was completed in ambulatory basis in 20% of the patients. In 63% of cases, admission was done in the same day of surgery. In 3 patients (9%), tumor resection was not achieved, therefore, concordance between radiological and surgical resectability rate was 91%. Resectability rate was 24.1%. Surgical Mortality was 3.3%, with a global morbidity rate of 56.6%. Survival at one, two, three and, four years was 76.2%, 56.3%, 43%, y 27.3% respectively. Conclusions: technological development and coordination of efforts in multidisciplinary teams offer an accurate evaluation of tumor involvement, and may reduce the number of laparotomies without tumor resection. The application of a systematic and generalized multimodal treatment in pancreatic cancer is progressively showing a tendency of progressive increase in resectability and survival rates in pancreatic cancer.spaHumansAdultPancreatic NeoplasmsAgedAged, 80 and overMaleChemotherapy, AdjuvantPancreaticoduodenectomyStentsProspective StudiesHepatectomyMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsOxaliplatinOrganoplatinum CompoundsDeoxycytidineCarcinomaPancreatectomyNeoadjuvant TherapyKaplan-Meier EstimateSurvival RateColectomyFemalePatient Care TeamLiver NeoplasmsCholangiopancreatography, Endoscopic RetrogradeCarcinoma, Pancreatic DuctalCombined Modality TherapyDiagnostic ImagingAged, 80 and overresearch articleAdultoColectomíaNeoplasias PancreáticasPancreaticoduodenectomíaCarcinoma Ductal PancreáticoFemeninoNeoplasias HepáticasStentsMasculinoCarcinomaHepatectomíaPersona de Mediana EdadCompuestos OrganoplatinosEstudios ProspectivosProtocolos de Quimioterapia Combinada AntineoplásicaDesoxicitidinaEstimación de Kaplan-MeierQuimioterapia AdyuvantePancreatectomíaTasa de SupervivenciaTerapia CombinadaTerapia NeoadyuvanteColangiopancreatografia Retrógrada EndoscópicaDiagnóstico por ImagenGrupo de Atención al PacienteHumanosAncianoAnciano de 80 o más AñosOxaliplatinoAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinomaCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantCholangiopancreatography, Endoscopic RetrogradeColectomyCombined Modality TherapyDeoxycytidineDiagnostic ImagingFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinPancreatectomyPancreatic NeoplasmsPancreaticoduodenectomyPatient Care TeamProspective StudiesStentsSurvival Rate2340-416721341931L627163222000288843100002Pancreatic cancerMultidisciplinaryMultimodal Therapy